Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02448550 · ClinicalTrials.gov registry record · Phase 3
Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial
A Phase 3 study, sponsored by Kaiser Permanente.
- Terminated
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT02448550 is a Phase 3 study that was terminated before completion, run by Kaiser Permanente. The registered enrollment target is 250 participants.
The verdict
NCT02448550, a Phase 3 study, was terminated before completion, sponsored by Kaiser Permanente.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether bivalirudin is non-inferior to unfractionated heparin in patients with stable angina, unstable angina, or non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Interventions
- DRUG Bivalirudin
- DRUG Unfractionated heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-06-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02448550
The ClinicalTrials.gov registry entry for NCT02448550 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bivalirudin is the first listed.
NCT02448550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02448550 about?
NCT02448550 is a clinical study titled "Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial". The purpose of this trial is to determine whether bivalirudin is non-inferior to unfractionated heparin in patients with stable angina, unstable angina, or non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
What is the current status of trial NCT02448550?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2015-05. Estimated completion is 2016-06-16.
What interventions are being tested in trial NCT02448550?
The interventions under investigation include: Bivalirudin (DRUG), Unfractionated heparin (DRUG).
Who is sponsoring clinical trial NCT02448550?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.